Dr. Andreas Krause to Present on Statistical Considerations for Model Selection and Bias; Dr. Klaas Prins to Present on Modeling and Simulation
MOUNTAIN VIEW, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that Pharsight senior scientists will deliver two presentations to biopharmaceutical industry statisticians attending the annual ROeS Seminar (Austrian-Swiss Region of the International Biometric Society), to be held in Bern, Switzerland on September 9-13, 2007. Andreas Krause, Ph.D., senior biostat-istician, Strategic Consulting Services, will present a model-based approach to assess clinical study data for potentially confounding effects; Klaas Prins, Ph.D., senior scientist, Strategic Consulting Services, will present methods for extracting and integrating public-source scientific literature in modeling and simulation analyses.
Drs. Krause and Prins will present applied case studies at two ROeS seminar sessions, each of which will provide a forum for pharmaceutical scientists from industry and academia to have a collaborative exchange on model-based approaches. Pharsight's two presentations are:
-- September 10: Modeling and simulation to adjust p-values in presence
of a regression to the mean effect.
Dr. Krause will present this case study as part of a dedicated
conference session on selection procedures and bias. The session will
include applied examples of statistical methods to enable model-based
drug development, and will describe research on how modeling and
simulation has been used to analyze and monitor clinical information.
-- September 11: Modeling and simulation using metadata: away from
inventing the wheel again.
Dr. Prins will present this case study as part of a dedicated
conference session on methods in meta analysis. The session will
include applied examples of modeling and simulation in several
therapeutic areas, and will describe research on how models based on
subject-level data and summary trial data have been used to predict
drug candidate performance, capture development knowledge, and support
the design of future clinical studies.
Additional information can be found at http://www.meduniwien.ac.at/ROeS/
"Model-based drug development continues to show value for optimizing drug therapy and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development can benefit from the application of novel statistical methods and quantitative models to simulate expected clinical responses of new compounds, to support critical program strategies and to enhance study design decisions. Pharsight is pleased to participate at the annual ROeS Seminar, and to exchange information with industry colleagues on the strategic use of modeling and simulation."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com. Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation.
|SOURCE Pharsight Corporation|
Copyright©2007 PR Newswire.
All rights reserved